Intrathecal Baclofen Therapy

作者: Marc Sindou , George Georgoulis , Patrick Mertens

DOI: 10.1007/978-3-7091-1771-2_6

关键词:

摘要: Baclofen, a γ-aminobutyric acid-B (GABA-B) receptor agonist, has direct action on the receptors of dorsal horn gray matter, where density GABA-B is high. Baclofen activates presynaptic that inhibit release excitatory neurotransmitters horn, particularly aspartate and glutamate. The excitability monosynaptic polysynaptic reflexes spinal cord becomes thereby reduced. Given orally, baclofen weak capacity to penetrate blood–central nervous system barrier. After oral administration drug absorbed by more than 80 % through intestinal mucosa plasmatic concentration maximal within 90–120 min; most eliminated urinary excretion. Failure medication produce sufficient reduction spasticity due poor passage across In animal experiments, in cerebrospinal fluid (CSF) was less one-tenth plasma level. Systemic delivery would same concentrations along be distributed equally brain, consequences somnolence or even coma. To circumvent this problem, Penn Kroin introduced developed method delivering intrathecally subarachnoid lumbar infusion.

参考文章(95)
William D. Steers, Jay M. Meythaler, Charles Haworth, Duke Herrell, T.S. Park, Effects of acute bolus and chronic continuous intrathecal baclofen on genitourinary dysfunction due to spinal cord pathology. The Journal of Urology. ,vol. 148, pp. 1849- 1855 ,(1992) , 10.1016/S0022-5347(17)37048-9
Patricia Nance, Orpha Schryvers, Brian Schmidt, Hy Dubo, Brenda Loveridge, Derek Fewer, Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Canadian Journal of Neurological Sciences. ,vol. 22, pp. 22- 29 ,(1995) , 10.1017/S0317167100040452
B. Sallerin-Caute, Y. Lazorthes, R. Bastide, CSF pharmacokinetic of intrathecal Baclofen administration Springer, Vienna. pp. 95- 95 ,(1991) , 10.1007/978-3-7091-6708-3_14
H. Müller, J. Zierski, D. Dralle, D. Krauß, E. Mutschler, Pharmacokinetics of Intrathecal Baclofen Springer, Berlin, Heidelberg. pp. 223- 226 ,(1988) , 10.1007/978-3-642-72954-6_17
Keberle H, Faigle Jw, The chemistry and kinetics of Lioresal. Postgraduate Medical Journal. ,vol. 48, ,(1972)
Patrick Mertens, M. Parise, L. Garcia-Larrea, C. Benneton, M. F. Millet, M. Sindou, Long-term clinical, electrophysiological and urodynamic effects of chronic intrathecal baclofen infusion for treatment of spinal spasticity. Acta Neurochirurgica. ,vol. 64, pp. 17- 25 ,(1995) , 10.1007/978-3-7091-9419-5_5
Herman Rm, D'Luzansky Sc, Ippolito R, Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. The Clinical Journal of Pain. ,vol. 8, pp. 338- 345 ,(1992)
Buffery S, Tan E, Perlman D, Silbert Pl, Stewart-Wynne Eg, Intrathecal baclofen for severe spasticity: five years experience. Clinical and experimental neurology. ,vol. 28, pp. 244- ,(1991)
April Saval, Anthony E. Chiodo, Effect of intrathecal baclofen concentration on spasticity control: case series. Journal of Spinal Cord Medicine. ,vol. 31, pp. 394- 397 ,(2008) , 10.1080/10790268.2008.11760742
A. Leland Albright, Technique for insertion of intraventricular baclofen catheters. Journal of Neurosurgery. ,vol. 8, pp. 394- 395 ,(2011) , 10.3171/2011.7.PEDS11211